5-{4-[4-(trifluoromethyl)phenyl]phenyl}pentanoic acid | 859169-92-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-{4-[4-(trifluoromethyl)phenyl]phenyl}pentanoic acid
• 英文别名: 5-[4-[4-(trifluoromethyl)phenyl]phenyl]pentanoic acid
• CAS: 859169-92-9
• 化学式: C₁₈H₁₇F₃O₂
• 分子量: 322.327
• InChiKey: XKVVZNRHJFFOAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  5-(4-溴苯基)戊酸 、 4-三氟甲基苯硼酸 在 sodium carbonate 作用下， 以 水 、 异丙醇 为溶剂， 反应 0.17h， 以32%的产率得到5-{4-[4-(trifluoromethyl)phenyl]phenyl}pentanoic acid
  参考文献：
  名称：

  4-aryl piperidines

  摘要：

  本发明涉及4-芳基哌啶及其相关杂环化合物，这些化合物是黑素聚集激素-1（MCH1）受体的选择性拮抗剂。本发明提供了一种药物组合物，包括治疗有效量的本发明的化合物和药用可接受的载体。本发明还提供了一种通过结合治疗有效量的本发明的化合物和药用可接受的载体来制造的药物组合物。本发明进一步提供了一种制造药物组合物的方法，包括结合治疗有效量的本发明的化合物和药用可接受的载体。本发明还提供了一种减少主体体质量的方法，包括向主体施用有效减少主体体质量的本发明的化合物的量。本发明进一步提供了一种治疗患有抑郁和/或焦虑的主体的方法，包括向主体施用有效治疗主体的抑郁和/或焦虑的本发明的化合物的量。

  公开号：

  US20050154022A1

文献信息

• 4-ARYL PIPERIDINES
  申请人：H.Lundbeck A/S

  公开号：EP1708704A2

  公开（公告）日：2006-10-11
• EP1708704A4
  申请人：——

  公开号：EP1708704A4

  公开（公告）日：2009-08-05
• MATRIX METALLOPROTEINASE INHIBITORS
  申请人：Ranbaxy Laboratories Limited

  公开号：EP2074093A2

  公开（公告）日：2009-07-01
• [EN] 4-ARYL PIPERIDINES<br/>[FR] 4-ARYLE PIPERIDINES
  申请人：LUNDBECK & CO AS H

  公开号：WO2005069834A2

  公开（公告）日：2005-08-04

  This invention is directed to 4-aryl piperidines and related heterocyclic compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject’s depression and/or anxiety.
• [EN] MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA MÉTALLOPROTÉINASE MATRICIELLE
  申请人：RANBAXY LAB LTD

  公开号：WO2008023336A2

  公开（公告）日：2008-02-28

  [EN] The present invention relates to ß-hydroxy and amino substituted carboxylic acids, which act as matrix metalloprotease inhibitors, particularly diastereomerically pure ß-hydroxy carboxylic acids, corresponding processes for the synthesis of and pharmaceutical compositions containing the compounds of the present invention. Compounds of the present invention are useful in the treatment of various inflammatory, autoimmune and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over- activation of a matrix metalloproteinase using the compounds.
  [FR] La présente invention concerne des acides carboxyliques à substitution ß-hydroxy et amino qui agissent en tant qu'inhibiteurs de la métalloprotéase matricielle, en particulier des acides ß-hydroxy carboxyliques purs sur le plan diastéréomérique. L'invention concerne également les procédés correspondants de synthèse des composés de la présente invention et des compositions pharmaceutiques contenant lesdits composés. Les composés de la présente invention sont utilisables pour le traitement de diverses maladies inflammatoires, auto-immunes et allergiques, telles que l'asthme, la polyarthrite rhumatoïde, la bronchopneumopathie chronique obstructive (Chronic Obstructive Pulmonary Disease : COPD), la rhinite, l'arthrose, le psoriasis arthropathique, le psoriasis, la fibrose pulmonaire, les retards de cicatrisation, l'inflammation pulmonaire, le syndrome de détresse respiratoire aiguë, la parodontite, la sclérose en plaques, la gingivite, l'athérosclérose, la prolifération néointimale qui conduit à la resténose et à l'insuffisance cardiaque ischémique, les attaques, les maladies rénales, la métastase tumorale et d'autres affections inflammatoires caractérisées par la sur-expression et la sur-activation d'une métalloprotéase matricielle, à l'aide des composés.